Andres Gomez-Caminero
Research Subjects
Andres Gomez-Caminero has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
Caryn Lerman
Lombardi Cancer Center, Georgetown University Medical Center
3 shared publications- Caryn Lerman
Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007-4104, USA
2 shared publications Chanita Hughes
Georgetown University Medical Center, Lombardi Cancer Center, Washington, DC 20007, USA
2 shared publications- Gregory A. Nichols
Kaiser Permanente Center for Health Research, Portland, Oregon
2 shared publications - Irva Hertz-Picciotto
Department of Public Health Sciences, School of Medicine, University of California, Davis, CA 95616, USA
2 shared publications - Ishan Hirji
Bristol-Myers Squibb Co., USA
2 shared publications
Latest Publications
- Open Access
- 10 January 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (1) , e0311935
Patterns of belatacept use and risk of post-transplant lymphoproliferative disorder in US kidney transplant recipients: An analysis of the Organ Procurement and Transplantation Network database
Background: Belatacept is approved for the prophylaxis of organ rejection in Epstein-Barr virus (EBV)-seropositive kidney transplant recipients and is associated with a risk of post-transplant lymphoproliferative disorder (PTLD). Methods: Data from the Organ Procurement and Transplantation Network were used to examine patterns of belatacept use, describe patient characteristics, and estimate risk of PTLD in EBV-seropositive, kidney-only transplant recipients receiving belatacept- or calcineurin inhibitor (CNI)-based immunosuppression as part of US Food and Drug Administration-mandated safety monitoring. Results: During the study period (June 15, 2011–June 14, 2016), 94.9% (1631/1719) of belatacept-treated and 89.7% (59,992/66,905) of CNI-treated patients with known EBV serostatus were EBV seropositive. Among EBV-seropositive patients, 50.2% (belatacept) and 56.8% (CNI) received a standard criteria donor kidney, 59.5% and 18.7% received basiliximab induction, and 22.9% and 50.8% received antithymocyte globulin induction. PTLD developed in nine belatacept-treated patients (two with central nervous system [CNS] involvement) and 225 CNI-treated patients (nine with CNS involvement). Four and 81 patients, respectively, died due to PTLD. Kaplan–Meier analysis did not show a significant between-group difference in PTLD estimated incidence rates within 5 years (0.70% versus 0.48%, respectively; p = 0.18). Additionally, estimated PTLD incidence was not significantly different between treatment groups in a propensity score matched cohort. Conclusions: The majority of adult kidney-only transplant recipients treated with belatacept in routine clinical practice are EBV seropositive. In this study, the risk of PTLD in these patients, while higher than for CNI-based immunosuppression, remained low after adjusting for differences in patient characteristics. Trial registration: These studies are registered at ClinicalTrials.gov: NCT01670058 and NCT01656343.
- 10 January 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (1) , e0311935
Open AccessPatterns of belatacept use and risk of post-transplant lymphoproliferative disorder in US kidney transplant recipients: An analysis of the Organ Procurement and Transplantation Network database
Background: Belatacept is approved for the prophylaxis of organ rejection in Epstein-Barr virus (EBV)-seropositive kidney transplant recipients and is associated with a risk of post-transplant lymphoproliferative disorder (PTLD). Methods: Data from the Organ Procurement and Transplantation Network were used to examine patterns of belatacept use, describe patient characteristics, and estimate risk of PTLD in EBV-seropositive, kidney-only transplant recipients receiving belatacept- or calcineurin inhibitor (CNI)-based immunosuppression as part of US Food and Drug Administration-mandated safety monitoring. Results: During the study period (June 15, 2011–June 14, 2016), 94.9% (1631/1719) of belatacept-treated and 89.7% (59,992/66,905) of CNI-treated patients with known EBV serostatus were EBV seropositive. Among EBV-seropositive patients, 50.2% (belatacept) and 56.8% (CNI) received a standard criteria donor kidney, 59.5% and 18.7% received basiliximab induction, and 22.9% and 50.8% received antithymocyte globulin induction. PTLD developed in nine belatacept-treated patients (two with central nervous system [CNS] involvement) and 225 CNI-treated patients (nine with CNS involvement). Four and 81 patients, respectively, died due to PTLD. Kaplan–Meier analysis did not show a significant between-group difference in PTLD estimated incidence rates within 5 years (0.70% versus 0.48%, respectively; p = 0.18). Additionally, estimated PTLD incidence was not significantly different between treatment groups in a propensity score matched cohort. Conclusions: The majority of adult kidney-only transplant recipients treated with belatacept in routine clinical practice are EBV seropositive. In this study, the risk of PTLD in these patients, while higher than for CNI-based immunosuppression, remained low after adjusting for differences in patient characteristics. Trial registration: These studies are registered at ClinicalTrials.gov: NCT01670058 and NCT01656343.
- Open Access
- 17 May 2024
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 10 (6) , e1644
Long-term Safety in Epstein–Barr Virus–Seropositive Kidney-only Transplant Recipients Treated With Belatacept in Clinical Practice: Final Study Results From the ENLiST Registry
Background.: Belatacept, a selective T-cell costimulation blocker, was associated with improved survival and renal function but also with a risk of posttransplant lymphoproliferative disorder (PTLD) in adult kidney transplant recipients in phase 3 trials. This registry examined long-term safety in Epstein–Barr virus (EBV)–seropositive kidney transplant recipients treated with belatacept. Methods.: This US-based, prospective, voluntary, multicenter registry (Evaluating Nulojix Long-Term Safety in Transplant [ENLiST]) included adult EBV-seropositive kidney-only transplant recipients treated de novo (within 14 d of transplantation) with belatacept. Primary objectives were to estimate incidence rates of confirmed PTLD, central nervous system (CNS) PTLD, and progressive multifocal encephalopathy (PML). The minimum follow-up was 2 y. Results.: Of 985 enrolled transplant recipients, 933 EBV-seropositive patients received belatacept, with 523 (56.1%) receiving concomitant tacrolimus at transplant (for up to 12 mo). By study end, 3 cases of non-CNS PTLD (incidence rate, 0.08/100 person-years), 1 case of CNS PTLD (0.03/100 person-years), and no cases of PML had been reported. Two patients with non-CNS PTLD received concomitant belatacept and tacrolimus and 1 received belatacept and lymphocyte-depleting therapy. Incidence rates were comparable between patients who received concomitant belatacept and tacrolimus and those who did not receive tacrolimus (0.09/100 person-years and 0.07/100 person-years, respectively; P = 0.96). Two of 4 patients with PTLD died, and 2 were alive at the end of the study. Cumulatively, 131 graft losses or deaths were reported by study end. Conclusions.: Our results from the ENLiST registry, a large, prospective real-world study, showed that the incidence rates of PTLD and CNS PTLD in belatacept-treated EBV-seropositive transplant recipients were consistent with findings from previous phase 3 trials.
- 17 May 2024
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 10 (6) , e1644
Open AccessLong-term Safety in Epstein–Barr Virus–Seropositive Kidney-only Transplant Recipients Treated With Belatacept in Clinical Practice: Final Study Results From the ENLiST Registry
Background.: Belatacept, a selective T-cell costimulation blocker, was associated with improved survival and renal function but also with a risk of posttransplant lymphoproliferative disorder (PTLD) in adult kidney transplant recipients in phase 3 trials. This registry examined long-term safety in Epstein–Barr virus (EBV)–seropositive kidney transplant recipients treated with belatacept. Methods.: This US-based, prospective, voluntary, multicenter registry (Evaluating Nulojix Long-Term Safety in Transplant [ENLiST]) included adult EBV-seropositive kidney-only transplant recipients treated de novo (within 14 d of transplantation) with belatacept. Primary objectives were to estimate incidence rates of confirmed PTLD, central nervous system (CNS) PTLD, and progressive multifocal encephalopathy (PML). The minimum follow-up was 2 y. Results.: Of 985 enrolled transplant recipients, 933 EBV-seropositive patients received belatacept, with 523 (56.1%) receiving concomitant tacrolimus at transplant (for up to 12 mo). By study end, 3 cases of non-CNS PTLD (incidence rate, 0.08/100 person-years), 1 case of CNS PTLD (0.03/100 person-years), and no cases of PML had been reported. Two patients with non-CNS PTLD received concomitant belatacept and tacrolimus and 1 received belatacept and lymphocyte-depleting therapy. Incidence rates were comparable between patients who received concomitant belatacept and tacrolimus and those who did not receive tacrolimus (0.09/100 person-years and 0.07/100 person-years, respectively; P = 0.96). Two of 4 patients with PTLD died, and 2 were alive at the end of the study. Cumulatively, 131 graft losses or deaths were reported by study end. Conclusions.: Our results from the ENLiST registry, a large, prospective real-world study, showed that the incidence rates of PTLD and CNS PTLD in belatacept-treated EBV-seropositive transplant recipients were consistent with findings from previous phase 3 trials.
- Open Access
- 10 November 2023
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 64, 152313
Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study
- 10 November 2023
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 64, 152313
Open AccessInfection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study
- 19 July 2021
- Published by Morressier GmbH
What Cannabis Related Data Is Reported in the Fda Faers Database
Welcome to the 2021 Virtual Cannabis Research Conference! This three-day, comprehensive conference explores new cannabis research frontiers in medicine, science, and society. Visit the CRC Virtual Exhibit Hall, between 8:00 am - 4:30 pm MT and meet the exhibitors. | Turn your camera & mic on and visit the CRC Virtual Networking Lounge. Mingle with other conference attendees around the clock. Visit: [Conference Program Book](https://online.fliphtml5.com/wowbk/dwbj/#p=1) | [Virtual Exhibit Hall](https://exhibithall.cannabisresearchconference.net/live/index.html) | [Virtual Networking Lounge](https://www.wonder.me/r?id=56fa86df-578b-4e0e-9ef5-064766ae5161) THE TIMES LISTED BELOW ARE IN YOUR TIME ZONE. PLEASE REFER TO THE PROGRAM BOOK FOR THE MOUNTAIN TIME ZONE.
- 19 July 2021
- Published by Morressier GmbH
What Cannabis Related Data Is Reported in the Fda Faers Database
Welcome to the 2021 Virtual Cannabis Research Conference! This three-day, comprehensive conference explores new cannabis research frontiers in medicine, science, and society. Visit the CRC Virtual Exhibit Hall, between 8:00 am - 4:30 pm MT and meet the exhibitors. | Turn your camera & mic on and visit the CRC Virtual Networking Lounge. Mingle with other conference attendees around the clock. Visit: [Conference Program Book](https://online.fliphtml5.com/wowbk/dwbj/#p=1) | [Virtual Exhibit Hall](https://exhibithall.cannabisresearchconference.net/live/index.html) | [Virtual Networking Lounge](https://www.wonder.me/r?id=56fa86df-578b-4e0e-9ef5-064766ae5161) THE TIMES LISTED BELOW ARE IN YOUR TIME ZONE. PLEASE REFER TO THE PROGRAM BOOK FOR THE MOUNTAIN TIME ZONE.
- Open Access
- 1 May 2017
- Published by Taylor & Francis in Clinical Pharmacology: Advances and Applications
- Vol. ume 9, 55-64
An integrated epidemiological and neural net model of the warfarin effect in managed care patients
Introduction: Risk assessment tools are utilized to estimate the risk for stroke and need of anticoagulation therapy for patients with atrial fibrillation (AF). These risk stratification scores are limited by the information inputted into them and a reliance on time-independent variables. The objective of this study was to develop a time-dependent neural net model to identify AF populations at high risk of poor clinical outcomes and evaluate the discriminatory ability of the model in a managed care population. Methods: We performed a longitudinal, cohort study within a health-maintenance organization from 1997 to 2008. Participants were identified with incident AF irrespective of warfarin status and followed through their duration within the database. Three clinical outcome measures were evaluated including stroke, myocardial infarction, and hemorrhage. A neural net model was developed to identify patients at high risk of clinical events and defined to be an “enriched” patient. The model defines the enrichment based on the top 10 minimum mean square error output parameters that describe the three clinical outcomes. Cox proportional hazard models were utilized to evaluate the outcome measures. Results: Among 285 patients, the mean age was 74±12 years with a mean follow-up of 4.3±2.6 years, and 154 (54%) were treated with warfarin. After propensity score adjustment, warfarin use was associated with a slightly increased risk of adverse outcomes (including stroke, myocardial infarction, and hemorrhage), though it did not attain statistical significance (adjusted hazard ratio [aHR] =1.22; 95% confidence interval [CI] 0.75–1.97; p=0.42). Within the neural net model, subjects at high risk of adverse outcomes were identified and labeled as “enriched.” Following propensity score adjustment, enriched subjects were associated with an 81% higher risk of adverse outcomes as compared to nonenriched subjects (aHR=1.81; 95% CI, 1.15–2.88; p=0.01). Conclusion: Enrichment methodology improves the statistical discrimination of meaningful endpoints when used in a health records-based analysis.
- 1 May 2017
- Published by Taylor & Francis in Clinical Pharmacology: Advances and Applications
- Vol. ume 9, 55-64
Open AccessAn integrated epidemiological and neural net model of the warfarin effect in managed care patients
Introduction: Risk assessment tools are utilized to estimate the risk for stroke and need of anticoagulation therapy for patients with atrial fibrillation (AF). These risk stratification scores are limited by the information inputted into them and a reliance on time-independent variables. The objective of this study was to develop a time-dependent neural net model to identify AF populations at high risk of poor clinical outcomes and evaluate the discriminatory ability of the model in a managed care population. Methods: We performed a longitudinal, cohort study within a health-maintenance organization from 1997 to 2008. Participants were identified with incident AF irrespective of warfarin status and followed through their duration within the database. Three clinical outcome measures were evaluated including stroke, myocardial infarction, and hemorrhage. A neural net model was developed to identify patients at high risk of clinical events and defined to be an “enriched” patient. The model defines the enrichment based on the top 10 minimum mean square error output parameters that describe the three clinical outcomes. Cox proportional hazard models were utilized to evaluate the outcome measures. Results: Among 285 patients, the mean age was 74±12 years with a mean follow-up of 4.3±2.6 years, and 154 (54%) were treated with warfarin. After propensity score adjustment, warfarin use was associated with a slightly increased risk of adverse outcomes (including stroke, myocardial infarction, and hemorrhage), though it did not attain statistical significance (adjusted hazard ratio [aHR] =1.22; 95% confidence interval [CI] 0.75–1.97; p=0.42). Within the neural net model, subjects at high risk of adverse outcomes were identified and labeled as “enriched.” Following propensity score adjustment, enriched subjects were associated with an 81% higher risk of adverse outcomes as compared to nonenriched subjects (aHR=1.81; 95% CI, 1.15–2.88; p=0.01). Conclusion: Enrichment methodology improves the statistical discrimination of meaningful endpoints when used in a health records-based analysis.
- 1 July 2013
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 24 (6) , 630-635
Adverse events in patients with liver cancer
This study aimed to further the understanding of the incidence of adverse events (AEs) in a population-based representative liver cancer population where there is currently a lack of knowledge. We carried out a retrospective cohort study using data from an administrative claims database between 1 January 2004 and 31 December 2010. Patients were included in the study if they had at least one primary liver cancer diagnosis [International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM): 155.0] and a metastatic diagnosis [ICD-9-CM: 196.x, 197.x (except 197.7), 198.x or 199.0]. We estimated the incidence rate (IR) and 95% confidence interval (CI) for each AE under study. Of the patients identified, 1292 fulfilled the inclusion and exclusion criteria. The most common AEs were nausea and vomiting (IR=878.5/1000 person-years; 95% CI=799.5-963.1). Other common AEs were hypertension (IR=648.7/1000 person-years; 95% CI=569.2-736.1) and hemorrhage (IR=580.0/1000 person-years; 95% CI=518.6-646.6). The least common AEs were rare dermatologic diseases such as Stevens-Johnson syndrome and toxic epidermal necrolysis where no cases were observed. The rates detailed in this analysis are helpful in understanding the benefit risk of treating patients with liver cancer in the real world. Although no formal comparisons were performed, the increased risk of certain events observed in sorafenib-treated patients from this analysis mirrors the risks reported on the label for sorafenib. Therefore, this analysis provided a reasonable assessment of the AEs that patients with liver cancer experience in the real world.
- 1 July 2013
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 24 (6) , 630-635
Adverse events in patients with liver cancer
This study aimed to further the understanding of the incidence of adverse events (AEs) in a population-based representative liver cancer population where there is currently a lack of knowledge. We carried out a retrospective cohort study using data from an administrative claims database between 1 January 2004 and 31 December 2010. Patients were included in the study if they had at least one primary liver cancer diagnosis [International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM): 155.0] and a metastatic diagnosis [ICD-9-CM: 196.x, 197.x (except 197.7), 198.x or 199.0]. We estimated the incidence rate (IR) and 95% confidence interval (CI) for each AE under study. Of the patients identified, 1292 fulfilled the inclusion and exclusion criteria. The most common AEs were nausea and vomiting (IR=878.5/1000 person-years; 95% CI=799.5-963.1). Other common AEs were hypertension (IR=648.7/1000 person-years; 95% CI=569.2-736.1) and hemorrhage (IR=580.0/1000 person-years; 95% CI=518.6-646.6). The least common AEs were rare dermatologic diseases such as Stevens-Johnson syndrome and toxic epidermal necrolysis where no cases were observed. The rates detailed in this analysis are helpful in understanding the benefit risk of treating patients with liver cancer in the real world. Although no formal comparisons were performed, the increased risk of certain events observed in sorafenib-treated patients from this analysis mirrors the risks reported on the label for sorafenib. Therefore, this analysis provided a reasonable assessment of the AEs that patients with liver cancer experience in the real world.
- 1 November 2012
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 26 (6) , 501-505
Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database
- 1 November 2012
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 26 (6) , 501-505
Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database
- 1 November 2012
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 26 (6) , 513-516
Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD)
- 1 November 2012
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 26 (6) , 513-516
Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD)
- 26 April 2007
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 10 (2) , 183-184
Response to Olivarius and Siersma: Weight change or change in weight trend. Differences in analytical approaches (and differences in study samples)
- 26 April 2007
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 10 (2) , 183-184
Response to Olivarius and Siersma: Weight change or change in weight trend. Differences in analytical approaches (and differences in study samples)
- 7 August 2006
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 15 (11) , 799-807
Differential associations of beta‐blockers with hemorrhagic events for chronic heart failure patients on warfarin
Purpose: Beta‐blockers have many different physiologic effects that could potentially influence the risk of hemorrhagic events in chronic heart failure patients (CHF) on warfarin. We examined how different beta‐blockers vary in their associated risk of a hemorrhagic event.Methods: We used databases from the Department of Veterans Affairs (VA) that contain information on medications prescribed, diagnoses, and hospitalizations. We identified patients with CHF on warfarin and either metoprolol, carvedilol, atenolol, or no beta‐blocker during 1999–2001. We modeled time to first hemorrhagic event using a Cox proportional hazards model, adjusting for age, ethnicity, comorbidities, and other factors. INR levels were examined in a subsample of 3546 patients.Results: We identified 66 988 CHF patients on warfarin. Hemorrhagic events occurred in 15.3% of the sample and, in 3.8% of the sample, the hemorrhage was considered severe. Compared to patients on carvedilol, the hazards ratio for a new hemorrhagic event was 1.25 (1.17, 1.34) for no beta‐blocker, 1.27 (1.18, 1.38) for atenolol, and 1.38 (1.28, 1.48) for metoprolol. No differences in INR levels were evident among the four groups.Conclusions: The risk for a hemorrhagic event among CHF patients on warfarin may be affected by beta‐blocker use and varies depending on which beta‐blocker is prescribed. Copyright © 2006 John Wiley & Sons, Ltd.
- 7 August 2006
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 15 (11) , 799-807
Differential associations of beta‐blockers with hemorrhagic events for chronic heart failure patients on warfarin
Purpose: Beta‐blockers have many different physiologic effects that could potentially influence the risk of hemorrhagic events in chronic heart failure patients (CHF) on warfarin. We examined how different beta‐blockers vary in their associated risk of a hemorrhagic event.Methods: We used databases from the Department of Veterans Affairs (VA) that contain information on medications prescribed, diagnoses, and hospitalizations. We identified patients with CHF on warfarin and either metoprolol, carvedilol, atenolol, or no beta‐blocker during 1999–2001. We modeled time to first hemorrhagic event using a Cox proportional hazards model, adjusting for age, ethnicity, comorbidities, and other factors. INR levels were examined in a subsample of 3546 patients.Results: We identified 66 988 CHF patients on warfarin. Hemorrhagic events occurred in 15.3% of the sample and, in 3.8% of the sample, the hemorrhage was considered severe. Compared to patients on carvedilol, the hazards ratio for a new hemorrhagic event was 1.25 (1.17, 1.34) for no beta‐blocker, 1.27 (1.18, 1.38) for atenolol, and 1.38 (1.28, 1.48) for metoprolol. No differences in INR levels were evident among the four groups.Conclusions: The risk for a hemorrhagic event among CHF patients on warfarin may be affected by beta‐blocker use and varies depending on which beta‐blocker is prescribed. Copyright © 2006 John Wiley & Sons, Ltd.